The pioneering EGFR×HER3 dual-antibody ADC, the Class 1 new drug Yizekang® (luncon-yilongtuo monoclonal antibody, iza-bren) developed by Sichuan Biokin Pharmaceutical Co.,Ltd. (ASX: 688506), has received marketing approval domestically for the treatment of recurrent/metastatic nasopharyngeal carcinoma in later lines. This significant announcement released by the company on June 22 has garnered widespread market attention.
It is noteworthy that Yizekang® is a first-in-class, novel concept EGFR×HER3 dual-antibody ADC, and it is the world's first and only approved dual-antibody ADC new drug. This approval also marks the official entry of cancer treatment into a new era of dual-antibody ADCs. Driven by this major positive development and the company's solid fundamentals, the stock has entered a favorable valuation zone, with clear signals of a value transition emerging.
Commercial Launch of a Next-Generation Cornerstone Cancer Therapy
Earlier this year at the ASCO annual meeting, Yizekang® stood out with positive data from two Phase III trials. Now, with this major first-in-class/best-in-class molecule officially approved for market, the global industry and markets are highly anticipating its subsequent commercial performance.
The approved indication for Yizekang® is later-line nasopharyngeal carcinoma. Beyond this, the drug currently has at least 15 key Phase II/III clinical studies underway in China, covering high-incidence cancers such as lung cancer, esophageal squamous cell carcinoma, and breast cancer.
As the first pan-tumor platform ADC product, Yizekang® has already achieved positive results in three large-scale Phase III studies. In addition to the newly approved later-line nasopharyngeal carcinoma indication, its registration studies for second-line esophageal squamous cell carcinoma (ESCC) and second-line triple-negative breast cancer (TNBC) have also succeeded, with best-in-class level data readouts across these three major cancer domains, solidifying the product's logic as a globally significant drug.
For overseas markets, global strategic partner Bristol Myers Squibb (BMS) has formulated an extensive global development plan for iza-bren, covering monotherapy and combination therapy strategies and focusing on major indications like lung and breast cancer. This domestic approval marks the first step in Yizekang®'s accelerated journey to becoming a "next-generation cornerstone cancer therapy." Market projections suggest the drug's potential peak annual sales could reach $20 billion, indicating a very bright commercial outlook.
Heightened Investment Certainty from Accelerated Globalization
In recent years, as the company's globalization process has continuously accelerated, it has demonstrated strong global competitiveness across multiple cutting-edge innovation technology areas. Its own value proposition as a potential multinational corporation (MNC) and the certainty of its investment case are expected to be consistently validated.
A key component of this accelerated globalization was a 2023 strategic global collaboration with BMS for iza-bren, featuring a potential total deal value of up to $8.4 billion characterized by "high upfront payment, high milestone payments, and high royalties." This business development deal follows a co-development, co-commercialization (Co-CO) model where both parties share global research efforts and returns.
Engaging in deep Co-CO collaboration with BMS not only serves as a powerful endorsement of the company's core R&D capabilities but is also a crucial move for the company to leverage a multinational pharmaceutical giant in its exploration of globalization.
Beyond partnerships, the company is also forging its own strategic path to build independent global capabilities, aiming to create a replicable and sustainable global growth model. A recent example is the FDA clearance for the global Phase III clinical trial of its DLL3 ADC candidate.
On June 5, the company announced that the Phase III clinical application for BL-M14D1 (DLL3 ADC) combined with immunotherapy for first-line extensive-stage small cell lung cancer (ES-SCLC) patients had received FDA clearance. This makes it the world's second DLL3 ADC drug to enter Phase III clinical development. It is also the world’s first Phase III clinical study of an ADC combined with immunotherapy in first-line ES-SCLC.
Notably, this clinical trial is being independently advanced by the company's U.S. subsidiary, Systimmune, with the company holding full global rights to BL-M14D1. This signifies that the company has established the capability to independently conduct global Phase III clinical trials.
In fact, backed by sustained investment in capital and R&D teams in recent years, the company has built a differentiated innovation pipeline combining independent R&D and international collaboration, anchored in its two major R&D centers in China and the U.S., and holds full rights to numerous best-in-class molecules. The current independent global development progress of BL-M14D1 serves as a leading example, giving investors confidence that subsequent major BIC molecules can replicate this successful global development path under the company's guidance, propelling the firm firmly towards becoming a global MNC and further enhancing investment certainty.
Financial Foundation and Outlook
From a financial perspective, the company currently holds nearly 10 billion yuan in cash reserves. This, combined with an expected $250 million milestone payment in the second half of this year and the commencement of commercial self-sustaining revenue, will further bolster the company's financial safety net.
Looking ahead, whether through restarting its Hong Kong IPO fundraising or employing flexible financing strategies, the company's financial resources are expected to be further strengthened, laying a solid foundation for the continued expansion of its global R&D and commercialization efforts and the acceleration of its MNC transformation.
Against this backdrop, although there has been a recent divergence between the company's stock price and its robust fundamentals, considering the successful market approval of its core product Yizekang® and the company's continuously demonstrated MNC potential, its intrinsic value is in urgent need of reassessment. Once market sentiment stabilizes and a sector trend reversal is established, the company's stock price is expected to be among the first to break out of its volatile range, demonstrating considerable upward potential to market investors.
Comments